CBD killed kidney cancer cells in lab dishes but lost effectiveness with serum and showed no selectivity for tumor over normal cells

CBD decreased renal cell carcinoma (RCC) cell viability and proliferation dose-dependently and induced reactive oxygen species accumulation. However, non-tumoral kidney cells showed comparable sensitivity (no tumor selectivity), and serum supplementation markedly attenuated all effects due to CBD's high protein binding.

Human RCC cell lines (Caki-1 and 769-P) and non-tumoral renal cells (HK-2) were treated with CBD (1-100 mcM) for up to 48 hours under serum-free and 5% serum conditions. Cell viability was assessed by MTT assay and ROS/RNS levels by fluorescence assay.

This study is a reality check for CBD-as-cancer-treatment claims. While CBD does kill cancer cells in a dish, it equally kills normal kidney cells and loses potency when serum proteins are present, highlighting the gap between laboratory findings and clinical applicability.

Many in vitro studies of CBD and cancer use serum-free conditions, which may overestimate CBD's therapeutic potential. This study explicitly tests both conditions and concludes with major translational limitations, a finding that deserves more attention.

In vitro study only. The concentrations showing effects exceed clinically achievable plasma levels. Only two RCC cell lines tested. Serum conditions in vitro may not perfectly model in vivo protein binding.